A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer

Men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer (NEPC/AVPC) have a poor prognosis and limited treatment options, and immunotherapy has not been tested in such patients. We conducted an open label single center phase 2 trial (NCT03179410) of men with progressive N...

Full description

Saved in:

Bibliographic Details
Published in:	Prostate cancer and prostatic diseases Vol. 25; no. 4; pp. 762 - 769
Main Authors:	Brown, Landon C, Halabi, Susan, Somarelli, Jason A, Humeniuk, Michael, Wu, Yuan, Oyekunle, Taofik, Howard, Lauren, Huang, Jiaoti, Anand, Monika, Davies, Catrin, Patel, Prekshaben, Staats, Janet, Weinhold, Kent J, Harrison, Michael R, Zhang, Tian, George, Daniel J, Armstrong, Andrew J
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.04.2022
Subjects:	Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - adverse effects Carcinoma, Neuroendocrine - pathology Cell activation Central nervous system Coronaviruses COVID-19 CXCR2 protein Histology Humans Immune system Immunotherapy Lymphocytes T Male Medical prognosis Metastases Middle Aged Monoclonal antibodies MSH2 protein Mutation Pandemics Patients PD-L1 protein Peripheral blood Phenotyping Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Remission Response rates Safety Survival Targeted cancer therapy Toxicity
ISSN:	1365-7852, 1476-5608, 1476-5608
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!